open access

Vol 7, No 2 (2004)
Short communications
Published online: 2004-06-02
Submitted: 2012-01-23
Get Citation

Myocardial perfusion in women with systemic lupus erythomatosus and no symptoms of coronary artery disease

Zenobia Czuszyńska, Grzegorz Romanowicz
Nucl. Med. Rev 2004;7(2):171-174.

open access

Vol 7, No 2 (2004)
Short communications
Published online: 2004-06-02
Submitted: 2012-01-23

Abstract

BACKGROUND: The aim of the study was to assess myocardial perfusion in women with systemic lupus erythomatosus (SLE) and no symptoms of coronary artery disease (CAD).
MATERIAL AND METHODS: Twenty two women with SLE of mean age 40.5 ± 7.2 were enrolled in the study. The average duration time of the disease was from 2 to 19 years, mean 8 ± 4.6 years. The inclusion criterion was the absence of stenocardial symptoms. The myocardial perfusion was studied by using Single Photon Emission Computerized Tomography (SPECT) utilising 99mTc-MIBI ands a triple-head gamma-camera. We also analyzed risk factors of heart ischemic disease in our group.
RESULTS: Myocardial perfusion stress scanning showed abnormal perfusion in 12 patients, 54.5% of the whole group, mostly in the anterior wall. At rest hypoperfusion abnormalities were found in 7 individuals. In patients with positive myocardial perfusion, out scanning, risk factors of CAD were more pronounced than in a sub-group with a negative result of myocardial perfusion scanning.
CONCLUSIONS: In young women with SLE and no symptoms of coronary artery disease, myocardial pefusion defects may be detected by means of myocardial perfusion scintigraphy. Exercise and resting electrocardiography tests could be not sufficient for CAD diagnosis in women with SLE. The presence of coronary artery disease risk factors in women with SLE could be an indication to perform myocardial perfusion SPECT scanning.

Abstract

BACKGROUND: The aim of the study was to assess myocardial perfusion in women with systemic lupus erythomatosus (SLE) and no symptoms of coronary artery disease (CAD).
MATERIAL AND METHODS: Twenty two women with SLE of mean age 40.5 ± 7.2 were enrolled in the study. The average duration time of the disease was from 2 to 19 years, mean 8 ± 4.6 years. The inclusion criterion was the absence of stenocardial symptoms. The myocardial perfusion was studied by using Single Photon Emission Computerized Tomography (SPECT) utilising 99mTc-MIBI ands a triple-head gamma-camera. We also analyzed risk factors of heart ischemic disease in our group.
RESULTS: Myocardial perfusion stress scanning showed abnormal perfusion in 12 patients, 54.5% of the whole group, mostly in the anterior wall. At rest hypoperfusion abnormalities were found in 7 individuals. In patients with positive myocardial perfusion, out scanning, risk factors of CAD were more pronounced than in a sub-group with a negative result of myocardial perfusion scanning.
CONCLUSIONS: In young women with SLE and no symptoms of coronary artery disease, myocardial pefusion defects may be detected by means of myocardial perfusion scintigraphy. Exercise and resting electrocardiography tests could be not sufficient for CAD diagnosis in women with SLE. The presence of coronary artery disease risk factors in women with SLE could be an indication to perform myocardial perfusion SPECT scanning.
Get Citation
About this article
Title

Myocardial perfusion in women with systemic lupus erythomatosus and no symptoms of coronary artery disease

Journal

Nuclear Medicine Review

Issue

Vol 7, No 2 (2004)

Pages

171-174

Published online

2004-06-02

Bibliographic record

Nucl. Med. Rev 2004;7(2):171-174.

Authors

Zenobia Czuszyńska
Grzegorz Romanowicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl